# Phase 1 Clinical Trial: Carbapenem-resistant Enterbacterales (CRE)

> **NIH NIH N01** · DYNPORT VACCINE COMPANY, LLC · 2022 · $2,320,888

## Abstract

The Phase I Clinical Trial Units provide a vehicle for the investigation of new therapeutic and immunomodulatory agents for the treatment of infectious disease.

## Key facts

- **NIH application ID:** 10655939
- **Project number:** 272201500005I-0-759302200057-2
- **Recipient organization:** DYNPORT VACCINE COMPANY, LLC
- **Principal Investigator:** GRAIG SHOCKEY
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $2,320,888
- **Award type:** —
- **Project period:** 2021-12-14 → 2023-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10655939

## Citation

> US National Institutes of Health, RePORTER application 10655939, Phase 1 Clinical Trial: Carbapenem-resistant Enterbacterales (CRE) (272201500005I-0-759302200057-2). Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/grant/nih/10655939. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*